In this short summary of our main educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies, and first- and second-line treatment options for these patients.

The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment. The experts also discuss how to treat patients who have co-mutations detected during testing.

This is an informative podcast discussion that culminates in some interesting key messages from two well-recognised Experts in NSCLC.

Key clinical takeaways:
- Test all patients irrespective of histology and smoking history
- Test upfront so that more efficacious agents can be used earlier in the patient journey
- Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed
- There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles

This is the full video. Get the shorter highlights video here: https://www.youtube.com/watch?v=UZPBUAFOwcY

Prefer to listen on the go? You can find this episode on your favourite podcast platform and download the transcript here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/

Follow us on social media:
X
LinkedIn

This video is supported by an Independent Education Grant from Pierre Fabre Laboratories.
This content is intended for healthcare professionals outside of the UK and ROI only.

The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.

This video is developed by cor2ed.com

Published November 2024